Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 2259 Published: October 31, 2021 Report Code: GMDGDHC13144IDB

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy, or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

The endometrial cancer drugs in development market research report provides an overview of the pipeline landscape. The report provides comprehensive information on the therapeutics under development for endometrial cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for endometrial cancer and features dormant and discontinued projects.

What are the targets of the endometrial cancer pipeline drugs market?

Some of the targets of the endometrial cancer pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 3, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Mast/Stem Cell Growth Factor Receptor Kit, and Fibroblast Growth Factor Receptor 3.

Endometrial cancer pipeline drugs market, by targets

Endometrial cancer pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the endometrial cancer pipeline drugs market?

The mechanisms of action of the endometrial cancer pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, and Fibroblast Growth Factor Receptor 3 Inhibitor.

Endometrial cancer pipeline drugs market, by mechanisms of action

Endometrial cancer pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the endometrial cancer pipeline drugs market?

The routes of administration in the endometrial cancer pipeline drugs market are oral, intravenous, parenteral, subcutaneous, intratumor, intravenous drip, intraperitoneal, topical, intravesical, and inhalational.

Endometrial cancer pipeline drugs market, by routes of administration

Endometrial cancer pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the endometrial cancer pipeline drugs market?

The molecule types in the endometrial cancer pipeline drugs market are small molecule, monoclonal antibody, monoclonal antibody conjugated, gene-modified cell therapy, synthetic peptide, cell therapy, fusion protein, oncolytic virus, biologic, and recombinant protein.

Endometrial cancer pipeline drugs market, by molecule types

Endometrial cancer pipeline drugs market, by molecule types

For more molecule types insights, download a free report sample

Which are the key companies in the endometrial cancer pipeline drugs market?

Some of the key companies in the endometrial cancer pipeline drugs market are AstraZeneca Plc, Incyte Corp, Novartis AG, Eisai Co Ltd, Eli Lilly and Co, Pfizer Inc, Advenchen Laboratories LLC, Alphamab Oncology, BeiGene Ltd, and Boehringer Ingelheim International GmbH.

Endometrial cancer pipeline drugs market, by key companies

Endometrial cancer pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 3, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Mast/Stem Cell Growth Factor Receptor Kit, and Fibroblast Growth Factor Receptor 3
Mechanisms of Action Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, and Fibroblast Growth Factor Receptor 3 Inhibitor
Routes of Administration Oral, Intravenous, Parenteral, Subcutaneous, Intratumor, Intravenous Drip, Intraperitoneal, Topical, Intravesical, and Inhalational
Molecule Types Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Synthetic Peptide, Cell Therapy, Fusion Protein, Oncolytic Virus, Biologic, and Recombinant Protein
Key Companies AstraZeneca Plc, Incyte Corp, Novartis AG, Eisai Co Ltd, Eli Lilly and Co, Pfizer Inc, Advenchen Laboratories LLC, Alphamab Oncology, BeiGene Ltd, and Boehringer Ingelheim International GmbH

This report provides:

  • A snapshot of the global therapeutic landscape of Endometrial cancer (Oncology).
  • Reviews of pipeline therapeutics for Endometrial cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key companies involved in Endometrial cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Endometrial cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Endometrial cancer (Oncology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometrial cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometrial cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Key Players

  • Aadi Bioscience Inc

    Ability Pharmaceuticals SL

    Abpro Corp

    Acrotech Biopharma LLC

    Adlai Nortye Biopharma Co Ltd

    Advenchen Laboratories LLC

    Agenus Inc

    Akeso Inc

    Allarity Therapeutics A/S

    Almac Discovery Ltd

    Alphamab Oncology

    Ambrx Biopharma Inc

    Amgen Inc

    Amphivena Therapeutics Inc

    Apexian Pharmaceuticals Inc

    Apexigen Inc

    Apollomics Inc

    Arch Oncology Inc

    Arcus Biosciences Inc

Table of Contents

Table of Contents

Introduction

Endometrial Cancer – Overview

Endometrial Cancer – Therapeutics Development

Endometrial Cancer – Therapeutics Assessment

Endometrial Cancer – Companies Involved in Therapeutics Development

Endometrial Cancer – Drug Profiles

Endometrial Cancer – Dormant Projects

Endometrial Cancer – Discontinued Products

Endometrial Cancer – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Endometrial Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Endometrial Cancer – Pipeline by Aadi Bioscience Inc, 2021

Endometrial Cancer – Pipeline by Ability Pharmaceuticals SL, 2021

Endometrial Cancer – Pipeline by Abpro Corp, 2021

Endometrial Cancer – Pipeline by Acrotech Biopharma LLC, 2021

Endometrial Cancer – Pipeline by Adlai Nortye Biopharma Co Ltd, 2021

Endometrial Cancer – Pipeline by Advenchen Laboratories LLC, 2021

Endometrial Cancer – Pipeline by Agenus Inc, 2021

Endometrial Cancer – Pipeline by Akeso Inc, 2021

Endometrial Cancer – Pipeline by Allarity Therapeutics A/S, 2021

Endometrial Cancer – Pipeline by Almac Discovery Ltd, 2021

Endometrial Cancer – Pipeline by Alphamab Oncology, 2021

Endometrial Cancer – Pipeline by Ambrx Biopharma Inc, 2021

Endometrial Cancer – Pipeline by Amgen Inc, 2021

Endometrial Cancer – Pipeline by Amphivena Therapeutics Inc, 2021

Endometrial Cancer – Pipeline by Apexian Pharmaceuticals Inc, 2021

Endometrial Cancer – Pipeline by Apexigen Inc, 2021

Endometrial Cancer – Pipeline by Apollomics Inc, 2021

Endometrial Cancer – Pipeline by Arch Oncology Inc, 2021

Endometrial Cancer – Pipeline by Arcus Biosciences Inc, 2021

Endometrial Cancer – Pipeline by Ascenta Therapeutics Inc, 2021

Endometrial Cancer – Pipeline by AstraZeneca Plc, 2021

Endometrial Cancer – Pipeline by Bantam Pharmaceutical LLC, 2021

Endometrial Cancer – Pipeline by Basilea Pharmaceutica Ltd, 2021

Endometrial Cancer – Pipeline by Bavarian Nordic A/S, 2021

Endometrial Cancer – Pipeline by Bayer AG, 2021

Endometrial Cancer – Pipeline by BeiGene Ltd, 2021

Endometrial Cancer – Pipeline by Beijing Neoantigen Biotechnology Co Ltd, 2021

Endometrial Cancer – Pipeline by Bellicum Pharmaceuticals Inc, 2021

Endometrial Cancer – Pipeline by Bicycle Therapeutics Plc, 2021

Endometrial Cancer – Pipeline by Bio-Path Holdings Inc, 2021

Endometrial Cancer – Pipeline by BioAtla Inc, 2021

Endometrial Cancer – Pipeline by BioMed Valley Discoveries Inc, 2021

Endometrial Cancer – Pipeline by BioNTech SE, 2021

Endometrial Cancer – Pipeline by BioSplice Therapeutics Inc, 2021

Endometrial Cancer – Pipeline by Biotheus Inc, 2021

Endometrial Cancer – Pipeline by Black Diamond Therapeutics Inc, 2021

Endometrial Cancer – Pipeline by Boehringer Ingelheim International GmbH, 2021

Endometrial Cancer – Pipeline by Bristol-Myers Squibb Co, 2021

Endometrial Cancer – Pipeline by Byondis BV, 2021

Endometrial Cancer – Pipeline by Calithera Biosciences Inc, 2021

Endometrial Cancer – Pipeline by CanBas Co Ltd, 2021

Endometrial Cancer – Pipeline by Carrick Therapeutics Ltd, 2021

Endometrial Cancer – Pipeline by Celon Pharma SA, 2021

Endometrial Cancer – Pipeline by Celsion Corp, 2021

Endometrial Cancer – Pipeline by Checkpoint Therapeutics Inc, 2021

Endometrial Cancer – Pipeline by Chimerix Inc, 2021

Endometrial Cancer – Pipeline by Clovis Oncology Inc, 2021

Endometrial Cancer – Pipeline by Coherent Biopharma, 2021

Endometrial Cancer – Pipeline by Compugen Ltd, 2021

Endometrial Cancer – Pipeline by Constellation Pharmaceuticals Inc, 2021

Endometrial Cancer – Pipeline by Context Therapeutics Inc, 2021

Endometrial Cancer – Pipeline by Corvus Pharmaceuticals Inc, 2021

Endometrial Cancer – Pipeline by Cotinga Pharmaceuticals Inc, 2021

Endometrial Cancer – Pipeline by CStone Pharmaceuticals Co Ltd, 2021

Endometrial Cancer – Pipeline by Cue Biopharma Inc, 2021

Endometrial Cancer – Pipeline by Cyclacel Pharmaceuticals Inc, 2021

Endometrial Cancer – Pipeline by CytomX Therapeutics Inc, 2021

Endometrial Cancer – Pipeline by Daiichi Sankyo Co Ltd, 2021

Endometrial Cancer – Pipeline by Deciphera Pharmaceuticals Inc, 2021

Endometrial Cancer – Pipeline by Dragonboat Biopharmaceutical (Shanghai) Co Ltd, 2021

Endometrial Cancer – Pipeline by Eisai Co Ltd, 2021

Endometrial Cancer – Pipeline by Eli Lilly and Co, 2021

Endometrial Cancer – Pipeline by Ella Therapeutics Ltd, 2021

Endometrial Cancer – Pipeline by Elucida Oncology Inc, 2021

Endometrial Cancer – Pipeline by ENB Therapeutics LLC, 2021

Endometrial Cancer – Pipeline by Esperance Pharmaceuticals Inc, 2021

Endometrial Cancer – Pipeline by Esperas Pharma Inc, 2021

Endometrial Cancer – Pipeline by EstryX Pharma Ltd, 2021

Endometrial Cancer – Pipeline by Evergreen Therapeutics Inc, 2021

Endometrial Cancer – Pipeline by Exelixis Inc, 2021

Endometrial Cancer – Pipeline by F-star Therapeutics Inc, 2021

Endometrial Cancer – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Endometrial Cancer – Pipeline by Fate Therapeutics Inc, 2021

Endometrial Cancer – Pipeline by Fujifilm Holdings Corp, 2021

Endometrial Cancer – Pipeline by Genelux Corp, 2021

Endometrial Cancer – Pipeline by Genentech USA Inc, 2021

Endometrial Cancer – Pipeline by Genmab AS, 2021

Endometrial Cancer – Dormant Projects, 2021

Endometrial Cancer – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Endometrial Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.